TP53 and breast cancer: Subsequently, we detected the cell proliferation inhibition activities of XR-4 in different wild-type p53 cancer cell lines via the CCK-8 (Cell Counting Kit-8) assay, including LNCaP (prostate cancer), 22Rv1 (prostate cancer), HepG2 (liver cancer), HCT116 (colorectal cancer), MCF7 (breast cancer), and T24 (bladder cancer) cell lines.